News

A greater proportion of patients treated with 0.25 mg/kg of tenecteplase were free from disability or achieved functional independence compared with those treated with 0.40 mg/kg doses, or alteplase.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

The cognitive neurologist at the University of California, San Francisco discussed a specific analysis that evaluated differences in cerebrospinal fluid in patients who develop cognitive changes following COVID-19 infection. [WATCH TIME: 6 minutes]

Regardless of baseline body mass index, patients who had increases or decreases of 5% or more in BMI had faster cognitive decline over a 5-year follow-up period.

After a prior phase 2 failure in CHANGE-MS showed signs of promise for progressive disease, the final patient visit has been completed in a trial of temelimab in relapsing disease, with results expected before the end of March 2022.

Overall, more than 40% of the cohort were eligible for a migraine preventive medication, but only 16.8% reported currently using one.

The association was found independent of vascular risk factors, suggesting a dose-response association between stroke severity and recurrence with risk of dementia.

Discussing recent technological advancements in the AD field, the founding executive director of the Alzheimer’s Drug Discovery Foundation noted the doors that these innovations have opened. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on the potential to detect patients at-risk for Alzheimer disease at an earlier age. [WATCH TIME: 4 minutes]

After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.

In addition to improving constipation in patients with Parkinson disease, ENT-01 also helped improve Mini-Mental State Examination scores, an exploratory measure of cognition.

The study is the first to support the validity of the ESS-CHAD in pediatric participants under the age of 12 years, showing internal consistency, test-retest reliability, responsiveness to change, and construct validity.

Neurology News Network for the week ending January 29, 2022.

An expert-led panel discuss the implications of recent findings that suggest a causative relationship between infection with Epstein-Barr virus and development of multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2022 that neurology health care professionals should keep their eyes on.

The cognitive neurologist at the University of California San Francisco discussed whether Alzheimer disease is a realistic fear for patients who’ve contracted COVID-19. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Bridget A. Bagert, MD, MPH. [LISTEN TIME: 32 minutes]

The light intervention was found to reduce awakening time at night, delay sleep offset, and advance sleep onset in a small patient population with dementia.

Chronic medical comorbidities, more commonly found in patients with obstructive sleep apnea, have been associated with higher readmission and healthcare utilization rates.

The founding executive director of the Alzheimer’s Drug Discovery Foundation spoke on the potential of drugs in the neuroprotection class for treatment of patients with AD. [WATCH TIME: 5 minutes]

Eighteen percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx, according to an announcement from Biogen and Eisai.

The cognitive neurologist at the University of California, San Francisco discussed the complexities in characterizing milder cognitive disorders and the need for more tailored assessments for these patients. [WATCH TIME: 8 minutes]

At 10 minutes post dose, all 3 AZ-009 dose groups showed a clear reduction from baseline in mean MDS-UPDRS part III score that was greater than for placebo.

Results from the cohort study suggest that a third dose was also associated with modestly increased levels of anti-SARS-CoV02 spike receptor-binding immunoglobulin G antibodies in those who had reduced protective humoral immunity before reimmunization.

After adjusting for baseline scores, no significant correlation emerged between the changes on Epworth Sleepiness Scale and the number of hours of CPAP use.